Recombinant Human IL-23R Fc Chimera Protein, CF

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human IL-23R Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its ability to inhibit IL-23 induced IL-17 secretion by mouse splenocytes. The ED₅₀ for this effect is 0.008-0.04 µg/mL in the presence of 0.3 ng/mL of rhIL-23.
• Source: Mouse myeloma cell line, NS0-derived human IL-23 R protein
  

  Human IL-23 R (Gly24 - Asp353) Accession # Q5VWK5	IEGRMD	Human IgG1 (Pro100 - Lys330)
  N-terminus		C-terminus

• Accession #: Q5VWK5
• N-terminal Sequence: Gly24
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Gene: IL23R
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 64 kDa (monomer).
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 95-105 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE under reducing conditions and visualized by silver stain
• Reconstitution Instructions: Reconstitute at 100 μg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human IL-23R Fc Chimera Protein, CF

• IBD17
• IL-23 R
• IL-23 receptor
• IL23R
• IL-23R
• interleukin 23 receptor
• interleukin-23 receptor

Background

Interleukin 23 (IL-23) is a heterodimeric cytokine composed of two disulfide-linked subunits, a p19 subunit that is unique to IL-23, and a p40 subunit that is shared with IL-12 (1 - 5). The functional IL-23 receptor complex consists of two receptor subunits, the IL-12 receptor beta 1 subunit (IL-12 R beta 1) and the IL-23-specific receptor subunit (IL-23 R) (3). Human IL-23 R cDNA encodes a 629 aa type I transmembrane protein with a 23 aa residue signal peptide, a 330 aa residue extracellular domain, a 23 aa residue transmembrane domain and a 253 aa residue cytoplasmic region. IL-23 R shares structural features with the IL-12 R beta 2, including an N-terminal Ig-like domain, two cytokine receptor domains and multiple glycosylation sites in the extracellular domain. IL-23 R lacks the three extracellular membrane-proximal fibronectin-type III domains present on IL-12 R beta 2. IL-23 R has a WQPWS sequence in the transmembrane-proximal cytokine receptor domain similar to the cytokine receptor signature WSXWS motif. The cytoplasmic region of IL-23 R has three potential Src homology 2 domain-binding sites and two potential Stat-binding sites. The gene for human IL-23 R is located on human chromosome 1 within 150 kb of IL-12 R beta 2. Human and mouse IL-23 R share 66% amino acid sequence identity. Based on quantitative real-time PCR, human IL-23 R mRNA is expressed in a human Th1 and Th0 clone as well as several NK cell lines and clones. Low but detectable levels of IL-23 R mRNA is also expressed in EBV-transformed B cells and activated PBMC. IL-23 initiates a signal transduction cascade similar to that of IL-12, and involves Jak2, Tyk2, Stat1, Stat3, Stat4, and Stat5. IL-23 has biological activities that are similar to, but distinct from IL-12.

1. Oppmann, B. et al. (2000) Immunity 13:715.
2. Lankford, C.S. and D.M. Frucht (2003) J. Leukoc. Biol. 73:49.
3. Parham, C. et al. (2002) J. Immunol. 168:5448.
4. Belladonna, M.L. et al. (2002) J. Immunol. 168:5448.
5. Aggarwal, S. et al. (2003) J. Biol. Chem. 278:1910.

Publications for IL-23R (1400-IR)(4)

Publications using 1400-IR

• KJ Roberts, MF Cubitt, TM Carlton, L Rodrigues-, L Maggiore, R Chai, S Clare, K Harcourt, TT MacDonald, KP Ray, A Vossenkämp, MR West, JS Crowe Preclinical development of a bispecific TNFalpha/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease Scientific Reports, 2021-09-30;11(1):19422. 2021-09-30 [PMID: 34593832] (ELISA Capture, Human)
• D Liu, S Xing, W Wang, X Huang, H Lin, Y Chen, K Lan, L Chen, F Luo, S Qin, R Liang, C Bai, J Xu, W Liu Prognostic value of serum soluble interleukin-23 receptor and related T-helper 17 cell cytokines in non-small cell lung carcinoma Cancer Sci., 2020-03-04;111(4):1093-1102. 2020-03-04 [PMID: 32020720] (ELISA Standard, Human)
• Yu RY, Gallagher G A naturally occurring, soluble antagonist of human IL-23 inhibits the development and in vitro function of human Th17 cells. J. Immunol., 2010-11-12;185(12):7302-8. 2010-11-12 [PMID: 21076058] (ELISA (Standard))
• Vaknin-Dembinsky A, Balashov K, Weiner HL IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production. J. Immunol., 2006-06-15;176(12):7768-74. 2006-06-15 [PMID: 16751425] (Bioassay, ELISA (Capture), Human)

Bioinformatics

• Gene Symbol: IL23R
• Uniprot:
  • Q5VWK5()